Mother leaning down touching foreheads with her son with CALD

let's recode the science

pipeline

Product Candidates
Severe Genetic Diseases
  • Pre-Clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • PH 2/3 
    Cerebral Adrenoleukodystrophy (Starbeam ALD-102)
  • PH 2/3 
    Cerebral Adrenoleukodystrophy (ALD-104)
  • PH 3 
    APVD IN EU
    TDT Non-β0/β0 genotypes (Northstar-2, HGB-207)
  • PH 3 
    TDT β0/β0 genotypes (Northstar-3, HGB-212)
  • PH 2/3 

    Planned: SCD (HGB-210)

  • PH 1/2 

    SCD (HGB-206)

  • PH 1 

    Sickle Cell Disease

  • PRE-C 

    Hurler Syndrome

  • PRE-C 

    Undisclosed

Oncology
  • Pre-Clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • PH 1 

    In Planning: Multiple Myeloma First Line

  • PH 2 

    Multiple Myeloma Second Line (KarMMa-2)

  • PH 3 

    Multiple Myeloma Third Line (KarMMa-3)

  • PH 2 

    Multiple Myeloma Fourth Line+ (KarMMa)

  • PH 1 

    CRB-401: Multiple Myeloma ≥3 Prior Lines

  • PH 1 

    CRB-402: Multiple Myeloma ≥3 Prior Lines

  • PH 1/2 

    Merkel Cell Carcinoma

  • PH 1/2 

    Solid Tumors

  • PRE-C 

    MAGE A4 Positive Solid Tumors

  • PRE-C 

    Diffuse Large B-Cell Lymphoma

  • PRE-C 

    Acute Myeloid Leukemia

  • PRE-C 

    Undisclosed

Clinical Trials

To learn more about our clinical studies of investigational gene therapies in transfusion-dependent β-thalassemia, severe sickle cell disease, cerebral adrenoleukodystrophy, and relapsed/refractory multiple myeloma, visit our clinical trials page.